BRAF and melanoma: However, the observed response rate has only been 56% in ATC, and based on studies in melanoma, it is expected that resistance will develop.23 Of interest, advanced PTC exhibits intrinsic resistance and a similar trial in BRAF-mutant PTC failed to show significant benefit for a BRAFi/MEKi combination compared to BRAFi alone.24 Thus, new therapeutic strategies are needed to combat mechanisms of resistance.